A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Oct 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VNDA SEC filings page.
Vanda Pharmaceuticals Inc. (VNDA) reported $229.3M in revenue over the twelve months to Sep 30, 2026, up 8.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue recovered modestly, but spending expanded far faster, turning a previously profitable business into a cash-consuming operation.
Revenue rose8.7% in FY2025, yet operating margin fell 49.5 percentage points, indicating expenses—not gross economics—absorbed the added sales. Gross margin held at94.0% while operating cash flow reached-$109.4M , so the deterioration occurred below the product-cost line rather than in manufacturing economics.
The cash profile weakened beyond capital spending: FY2025 free cash flow was
Total assets fell
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Vanda Pharmaceuticals Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Vanda Pharmaceuticals Inc. scores 11/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Vanda Pharmaceuticals Inc. scores 52/100 on it among other operating companies.
Vanda Pharmaceuticals Inc. carried $0.49 of total liabilities for every $1 of shareholders' equity at the end of fiscal year 2025. With no long-term debt figure for fiscal year 2025, Vanda Pharmaceuticals Inc. is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 56/100 among other operating companies measured the same way.
Vanda Pharmaceuticals Inc. held $2.39 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 2.39. Liquidity ranks operating companies on that ratio, and Vanda Pharmaceuticals Inc. scores 68/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Vanda Pharmaceuticals Inc. scores 8/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Vanda Pharmaceuticals Inc. scores 11/100 on it among other operating companies.
Vanda Pharmaceuticals Inc. scores -0.37, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $394.8M against total assets of $488.9M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Vanda Pharmaceuticals Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 operating efficiency signals passes.
Vanda Pharmaceuticals Inc. reported a net loss of $220.5M while operations used $109.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Vanda Pharmaceuticals Inc. generated $69.8M in revenue in Q3 2026. This represents an increase of 24.1% from the same quarter a year earlier. Against the prior quarter it is up 38.2%.
Vanda Pharmaceuticals Inc.'s EBITDA was -$21.3M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Vanda Pharmaceuticals Inc. reported a net loss of $22.6M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Vanda Pharmaceuticals Inc. earned -$0.37 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Vanda Pharmaceuticals Inc. recorded an outflow of $28.7M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Vanda Pharmaceuticals Inc. held $61.9M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Margins & Returns
Vanda Pharmaceuticals Inc.'s gross margin was 94.0% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.1 percentage points.
Vanda Pharmaceuticals Inc.'s operating margin was -33.7% in Q3 2026, reflecting core business profitability. This is up 21.9 percentage points from the same quarter a year earlier.
Vanda Pharmaceuticals Inc.'s net profit margin was -32.3% in Q3 2026, showing the share of revenue converted to profit. This is up 7.8 percentage points from the same quarter a year earlier.
Vanda Pharmaceuticals Inc.'s quarterly ROE was -11.3% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 6.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 17.1 percentage points.
Capital Allocation
Vanda Pharmaceuticals Inc. invested $27.6M in research and development in Q3 2026. This represents an increase of 22.4% from the same quarter a year earlier. Against the prior quarter it is down 25.3%.
Vanda Pharmaceuticals Inc. invested $311K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 93.2% from the same quarter a year earlier. Against the prior quarter it is up 63.7%.
Not reported for Q3 2026.
VNDA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $69.8M+24.1% | $50.5M-3.9% | $51.7M+3.4% | $57.2M+7.6% | $56.3M+18.1% | $52.6M+4.2% | $50.0M+5.4% | $53.2M+17.5% |
| Cost of Revenue | $4.2M+40.6% | $3.6M+30.1% | $3.2M-10.3% | $3.8M+48.0% | $3.0M+15.8% | $2.7M+0.1% | $3.5M+2.4% | $2.6M-25.1% |
| Gross Profit | $65.7M+23.2% | $47.0M-5.8% | $48.6M+4.4% | $53.4M+5.5% | $53.3M+18.2% | $49.9M+4.4% | $46.5M+5.7% | $50.6M+21.0% |
| R&D Expenses | $27.6M+22.4% | $37.0M+68.0% | $28.4M-20.4% | $29.0M+46.2% | $22.6M+34.5% | $22.0M+32.0% | $35.7M+68.8% | $19.8M-18.5% |
| SG&A Expenses | $59.6M-1.2% | $71.8M+11.2% | $68.4M+36.5% | $63.0M+60.3% | $60.3M+60.4% | $64.6M+63.7% | $50.1M+66.5% | $39.3M+66.4% |
| Operating Income | -$23.5Mn/m | -$63.8Mn/m | -$50.2Mn/m | -$40.4Mn/m | -$31.3Mn/m | -$38.5Mn/m | -$41.0Mn/m | -$10.3Mn/m |
| EBITDA | -$21.3Mn/m | -$61.6Mn/m | -$48.0Mn/m | -$38.3Mn/m | -$29.2Mn/m | -$36.5Mn/m | -$39.0Mn/m | -$8.3Mn/m |
| Income Tax | $174Kn/m | $129Kn/m | $143Kn/m | $103.2Mn/m | -$5.8Mn/m | -$7.7Mn/m | -$7.9Mn/m | -$1.6M-314.5% |
| Net Income | -$22.6Mn/m | -$62.5Mn/m | -$48.6Mn/m | -$141.2Mn/m | -$22.6Mn/m | -$27.2Mn/m | -$29.5Mn/m | -$4.9Mn/m |
| EPS (Basic) | -$0.37n/m | -$1.04n/m | -$0.82n/m | -$2.39n/m | -$0.38n/m | -$0.46n/m | -$0.50n/m | -$0.09n/m |
| EPS (Diluted) | -$0.37n/m | -$1.04n/m | -$0.82n/m | -$2.39n/m | -$0.38n/m | -$0.46n/m | -$0.50n/m | -$0.09n/m |
| Diluted Shares (Avg) | 60M+2.3% | 60M+2.1% | 59M+1.6% | N/A | 59M+1.4% | 59M+1.3% | 59M+1.3% | N/A |
Not reported in any period shown, so not listed: Interest Expense.
VNDA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $382.3M-36.4% | $412.5M-34.0% | $433.5M-31.4% | $488.9M-25.5% | $601.1M-6.8% | $624.7M-4.1% | $631.9M-3.2% | $656.2M+1.2% |
| Current Assets | $238.5M-35.1% | $264.5M-33.0% | $293.2M-28.1% | $347.3M-20.9% | $367.5M-15.0% | $394.9M-10.1% | $407.9M-7.2% | $438.9M+1.4% |
| Cash & Equivalents | $61.9M-11.6% | $55.9M-31.0% | $54.0M-51.7% | $84.9M-17.1% | $70.0M-30.3% | $81.0M-21.3% | $111.8M-10.7% | $102.3M-24.7% |
| Short-Term Investments | $78.6M-64.9% | $114.1M-53.3% | $148.3M-35.3% | $179.0M-34.3% | $223.7M-18.9% | $244.6M-14.1% | $229.1M-14.8% | $272.3M+7.9% |
| Inventory | $1.5M-25.2% | $1.7M-22.6% | $1.7M-11.6% | $1.9M+7.3% | $2.0M+26.5% | $2.2M+47.7% | $1.9M+27.8% | $1.7M+27.2% |
| Accounts Receivable | $60.3M+19.3% | $59.7M+32.7% | $56.9M+27.5% | $54.6M+15.9% | $50.5M+18.2% | $45.0M+7.5% | $44.6M+21.5% | $47.1M+37.9% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $182.5M+35.0% | $192.3M+38.9% | $152.8M+26.8% | $161.8M+37.5% | $135.1M+30.1% | $138.4M+27.2% | $120.5M+10.9% | $117.7M+13.6% |
| Current Liabilities | $155.0M+31.5% | $164.0M+35.0% | $135.6M+30.5% | $145.2M+45.2% | $117.9M+32.3% | $121.5M+29.5% | $103.9M+11.3% | $100.0M+14.0% |
| Non-Current Liabilities | $27.5M+59.2% | $28.3M+66.9% | $17.2M+3.5% | $16.6M-6.1% | $17.3M+16.7% | $16.9M+12.4% | $16.6M+8.2% | $17.7M+11.6% |
| Total Equity | $199.9M-57.1% | $220.2M-54.7% | $280.8M-45.1% | $327.2M-39.2% | $466.0M-13.9% | $486.3M-10.4% | $511.4M-6.0% | $538.5M-1.2% |
| Retained Earnings | -$528.4Mn/m | -$505.8Mn/m | -$443.3Mn/m | -$394.8Mn/m | -$253.6Mn/m | -$231.0Mn/m | -$203.8Mn/m | -$174.3Mn/m |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
VNDA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$28.4Mn/m | -$31.1Mn/m | -$50.2Mn/m | -$29.4Mn/m | -$31.6Mn/m | -$15.3Mn/m | -$33.1M-537.9% | -$1.8Mn/m |
| Depreciation & Amortization | $2.2M+8.6% | $2.3M+11.7% | $2.3M+14.0% | $2.1M+4.2% | $2.1M+4.4% | $2.0M+2.5% | $2.0M-10.8% | $2.0M+70.4% |
| Stock-Based Compensation | $2.3M+10.7% | $2.1M0.0% | $2.6M-13.7% | N/A | $2.1M-29.6% | $2.1M-29.5% | $3.0M-17.1% | N/A |
| Capital Expenditures | $311K+93.2% | $190K-36.5% | $221K-49.3% | $102K-52.3% | $161K0.0% | $299K+176.9% | $436K+6128.6% | $214K-15.4% |
| Free Cash Flow | -$28.7Mn/m | -$31.3Mn/m | -$50.4Mn/m | -$29.5Mn/m | -$31.8Mn/m | -$15.6Mn/m | -$33.6M-544.1% | -$2.0Mn/m |
| Investing Cash Flow | $35.2M+64.8% | $33.8Mn/m | $20.2M-53.9% | $44.9M+1023.6% | $21.4M+77.2% | -$15.3Mn/m | $43.9Mn/m | $4.0Mn/m |
| Financing Cash Flow | -$877Kn/m | -$856Kn/m | -$776Kn/m | -$640Kn/m | -$517Kn/m | -$425Kn/m | -$1.3Mn/m | -$155Kn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
VNDA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 94.0%-0.7pp | 93.0%-1.8pp | 93.9%+0.9pp | 93.3%-1.8pp | 94.8%+0.1pp | 94.8%+0.2pp | 93.0%+0.2pp | 95.1%+2.8pp |
| Operating Margin | -33.7%+21.9pp | -126.3% | -97.1%-15.1pp | -70.5%-51.2pp | -55.6%-32.5pp | -73.2%-53.1pp | -82.0%-62.5pp | -19.3%-3.7pp |
| Net Margin | -32.3%+7.8pp | -123.7% | -93.9%-35.0pp | -246.8% | -40.2%-29.0pp | -51.7%-42.8pp | -58.9%-50.2pp | -9.2%-3.9pp |
| Return on Equity | -11.3%-6.4pp | -28.4%-22.8pp | -17.3%-11.5pp | -43.2%-42.2pp | -4.9%-3.9pp | -5.6%-4.8pp | -5.8%-5.0pp | -0.9%-0.5pp |
| Return on Assets | -5.9%-2.1pp | -15.2%-10.8pp | -11.2%-6.5pp | -28.9%-28.1pp | -3.8%-2.9pp | -4.3%-3.7pp | -4.7%-4.0pp | -0.8%-0.4pp |
| Current Ratio | 1.54-1.6x | 1.61-1.6x | 2.16-1.8x | 2.39-2.0x | 3.12-1.7x | 3.25-1.4x | 3.93-0.8x | 4.39-0.5x |
| Liabilities-to-Equity | 0.91+0.6x | 0.87+0.6x | 0.54+0.3x | 0.49+0.3x | 0.29+0.1x | 0.28+0.1x | 0.240.0x | 0.220.0x |
| Asset Turnover | 0.18+0.1x | 0.120.0x | 0.120.0x | 0.120.0x | 0.090.0x | 0.080.0x | 0.080.0x | 0.080.0x |
| FCF Margin | -41.2%+15.3pp | -61.9%-32.3pp | -97.5%-30.4pp | -51.6%-47.8pp | -56.5%-25.6pp | -29.6%-15.6pp | -67.1%-83.0pp | -3.8%+5.0pp |
Not reported in any period shown, so not listed: Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. VNDA | FY2025 | $216.1M | -$220.5M | N/A | $226.8M | 34/100 |
| Arcturus Therapeutics Holdings Inc. ARCT | FY2025 | $82.0M | -$65.8M | -80.2% | $231.7M | 56/100 |
| Immuneering Corporation IMRX | FY2025 | N/A | -$56.0M | N/A | $226.7M | — |
| Q32 Bio Inc. QTTB | FY2025 | $53.7M | $29.8M | 55.5% | $255.3M | 46/100 |
| Protalix BioTherapeutics, Inc. PLX | FY2025 | $52.7M | -$6.6M | -12.5% | $254.6M | 41/100 |
| Rocket Pharmaceuticals, Inc. RCKT | FY2025 | $0 | -$223.1M | N/A | $235.6M | — |
Where Vanda Pharmaceuticals Inc. Ranks
Frequently Asked Questions
Vanda Pharmaceuticals Inc. (VNDA) reported $216.1M in total revenue for fiscal year 2025. This represents a 8.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Vanda Pharmaceuticals Inc. (VNDA) revenue grew by 8.7% year-over-year, from $198.8M to $216.1M in fiscal year 2025.
No, Vanda Pharmaceuticals Inc. (VNDA) reported a net loss of $274.8M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $220.5M.
Vanda Pharmaceuticals Inc. (VNDA) had EBITDA of -$140.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Vanda Pharmaceuticals Inc. (VNDA) had a gross margin of 94.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Vanda Pharmaceuticals Inc. (VNDA) had an operating margin of -70.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Vanda Pharmaceuticals Inc. (VNDA) has a return on equity of -67.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Vanda Pharmaceuticals Inc. (VNDA) recorded an outflow of $110.4M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Vanda Pharmaceuticals Inc. (VNDA) recorded an outflow of $109.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Vanda Pharmaceuticals Inc. (VNDA) had $488.9M in total assets as of fiscal year 2025, including both current and long-term assets.
Vanda Pharmaceuticals Inc. (VNDA) invested $998K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Vanda Pharmaceuticals Inc. (VNDA) invested $109.3M in research and development during fiscal year 2025.
Vanda Pharmaceuticals Inc. (VNDA) had a current ratio of 2.39 as of fiscal year 2025, which is generally considered healthy.
Vanda Pharmaceuticals Inc. (VNDA) had a liabilities-to-equity ratio of 0.49 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Vanda Pharmaceuticals Inc. (VNDA) had a return on assets of -45.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Vanda Pharmaceuticals Inc. (VNDA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $226.8M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Vanda Pharmaceuticals Inc. (VNDA) trades at 1.0x sales, its market capitalization divided by $229.3M revenue, trailing 12 months to September 30, 2026. The market capitalization is $226.8M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Vanda Pharmaceuticals Inc. (VNDA) held $263.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $109.4M over that year. Dividing the one by the other, the reported balance equals about 29 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Vanda Pharmaceuticals Inc. (VNDA) has an Altman Z-Score of -0.37, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Vanda Pharmaceuticals Inc. (VNDA) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Vanda Pharmaceuticals Inc. (VNDA) reported a net loss of $220.5M while operations used $109.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Vanda Pharmaceuticals Inc. (VNDA) scores 34 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.